Multiple sourcing Framework Contracts to speed up the development of and access to innovative medical countermeasures Next Generation Therapeutics for Infectious Diseases
Published deadline passed
The published deadline has passed. For multi-stage competitions a later tender deadline may still apply — check the notice or portal for the current phase.
- Qualification deadline
- Sep 2,Expired
- Award
- Price 20%
Brief
Health and Digital Executive Agency (HaDEA) needs services for multiple sourcing framework contracts to speed up the development of and access to innovative medical countermeasures, specifically Next Generation Therapeutics for Infectious Diseases, over 9 years, with a maximum total value of 252,000,000 EUR. The procurement aims to cover the development of innovative therapeutics to treat viral infections, ARDS or sepsis resulting from infections, including pathogen-targeted therapeutics (excluding small molecules or monoclonal antibodies) and host-targeted therapeutics. Broad spectrum, pathogen-agnostic, and therapeutics that reduce viral resistance are of particular interest. Offers will be evaluated based on quality (80%) and price (20%).
Forsknings- og utviklingsvirksomhet og tilhørende konsulenttjenester
Custom Assessment Criteria
Get answers to your bid/no-bid criteria
Set them up once and Cobrief answers them in every tender
Will you bid?
The agent sets up the bid and writes the first draft. Free for 14 days.
Award Criteria
Description
Please consult the procurement documents.
Source
No source found in the documents. Check the weight against the tender documents.
Description
Please consult the procurement documents.
Source
No source found in the documents. Check the weight against the tender documents.
Previous winners
Who are you up against?
The suppliers who have won similar contracts at Health and Digital Executive Agency (HaDEA) , HADEA - Health and Digital Executive Agency
From the notice
This call for tenders aims at speeding up the development of promising Next Generation Therapeutics for Infectious Diseases by adopting a competitive development in phases, under Pre-Commercial Procurement (PCP). The scope of the call is expected to cover the development of innovative therapeutics to treat viral infections, ARDS or sepsis resulting from infections, including pathogen-targeted therapeutics (but not small molecules or monoclonal antibodies) and host-targeted therapeutics, among which but not only direct-acting antivirals, indirect-acting antivirals and novel immune modulators. It may also cover innovative combinations therapies and products designed to be administered through alternative routes to IV. Broad spectrum therapeutics, pathogen-agnostic therapeutics and therapeutics that could reduce or counteract the emergence of viral resistance are of particular interest.
Contact
hadea-procurement@ec.europa.eu- Competition · Framework agreement · PrequalificationType
- 73000000Main codeResearch and development services and related consultancy services
- 73100000Research and experimental development services